[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-365473-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-365473-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","electrochemotherapy-for-recurrence-andor-metastatic-skin-cancers-a-prospective-case-series-in-iran","Electrochemotherapy for Recurrence and/or Metastatic Skin Cancers - A Prospective Case Series in Iran","","Purpose: This study investigated the efficacy of electrochemotherapy for three common skin cancer types: basal cell carcinoma (BCC), cutaneous squamous cell carcinoma (cSCC), and melanoma. Methods: Twenty-six patients were enrolled from single cancer treatment centers between 2022 and 2024. Electrochemotherapy treated all cancerous nodules in patients with multiple lesions, with the largest lesions prioritized for evaluation. Results: 104 nodules were assessed; 53 achieved clinical complete response after one month, and 51 showed partial response. The most frequent adverse effect was pain (65%). Conclusion: BCC had a higher clinical complete response rate, and ECT showed significant effectiveness for superficial tumors with predominantly temporary pain.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/healthcare/","Healthcare",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/electrochemotherapy-for-recurrence-andor-metastatic-skin-cancers-a-prospective-case-series-in-iran/365473/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/electrochemotherapy-for-recurrence-andor-metastatic-skin-cancers-a-prospective-case-series-in-iran/365473.png","ImageObject",300,407,{"name":42,"@type":43},"Kyle","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-28","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",16,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What skin cancer types were evaluated in this electrochemotherapy study?","Question",{"text":63,"@type":64},"The study evaluated basal cell carcinoma (BCC), cutaneous squamous cell carcinoma (cSCC), and melanoma.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How many patients and nodules were assessed, and what were the response outcomes after the first month?",{"text":68,"@type":64},"Twenty-six patients were included and 104 nodules were assessed. Clinical complete response occurred in 53 lesions and partial response in 51 lesions after the first month.",{"name":70,"@type":61,"acceptedAnswer":71},"What adverse effect was most common, and how was it characterized in the results?",{"text":72,"@type":64},"Pain was the most common adverse effect, occurring in 65% of cases, and side effects were predominantly temporary.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},365473,1790197866,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,110,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":108,"slug":109},7,40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":112,"show_sort_weight":113,"slug":114},8,"Research & Report",30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":107,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":140,"language":141,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":12,"update_tm":145,"read_time":113},3985741905716,"https://ap-avatar.wpscdn.com/davatar_994ba38a5ba835b3df7d355c54d3ed8d","Electrochemotherapy for Recurrence and/or Metastatic Skin Cancers: A Prospective Case Series in Iran  \nTechnology in Cancer Research & Treatment  \nVolume 24: 1-12 © The Author(s) 2025 Article reuse guidelines:  \n[sagepub.com/journals-permissions](sagepub.com/journals-permissions)[ ](sagepub.com/journals-permissions)[DOI: 10.1177/15330338251338635](DOI: 10.1177/15330338251338635)[ ](DOI: 10.1177/15330338251338635)[journals.sagepub.com/home/tct](journals.sagepub.com/home/tct)  \nSeyed Mojtaba YazdanParast, M.Sc. 1 , Sepideh Mansouri, PhD2,3,  \nFarshid Rostami Pouria, M.Sc.1, Navid Manoochehri, M.Sc. 1, Kosar Namakin4,  \nAlvand Naserghandi, PhD4, Seyed Rouhollah Miri, PhD5, Habibollah Mahmoodzadeh5, Omid Nabavian, PhD6 , Shirin Zaresharifi, PhD7, and Mohammad Abdolahad, PhD 1,2   \nAbstract  \nPurpose: This study aimed to investigate the efficacy of electrochemotherapy on the three common types of skin cancer, including basal cell carcinoma (BCC), cutaneous squamous cell carcinoma (cSCC), and melanoma.  \nMethods: 26 patients with skin cancer were recruited from single cancer treatment centers from 2022 to 2024 . Electrochemotherapy (ECT) was performed to treat the cancerous nodules; all nodules in a patient with multiple lesions were treated. However the biggest lesions were always pointed out (according to European Standard Operating Procedureson Electrochemotherapy protocol) and their clinical response and adverse effects were evaluated during the study.  \nResults: totally, 104 nodules of 26 patients were assessed. Clinical complete response was achieved in 53 lesions, while partial response was observed in 51 lesions after first month of treatment. The most common adverse effect was pain which was in 65% of cases.  \nConclusion: BCC shows a notably higher clinical complete response rate. Because the research was conducted at a single center and given the novelty of this treatment in Iran, the number of patients included in the study was limited. Electrochemotherapy (ECT) has shown significant clinical effectiveness for superficial tumors, especially for patients who have health issues related to standard therapies or who are resistant to conventional treatments. It is generally well-tolerated, with side effects predominantly consisting of temporary pain. Ongoing research aims to expand its use in deep-seated tumors that are resistant to conventional therapies.  \nKeywords  \nadverse effects, electrochemotherapy, skin cancer, response rate, electroporation  \nReceived: 7 January 2025; revised: 11 April 2025; accepted: 14 April 2025  \n1 Nano Electronic Center of Excellence, Nano Bio Electronic Devices Lab, School of Electrical and Computer Engineering, University of Tehran, Tehran, Iran 2UT and TUMS Cancer Electronics Research Center, Tehran University of Medical Sciences, Tehran, Iran  \n3Radiation Oncology Research Center (RORC), Cancer Institute, Tehran University of Medical Sciences, Tehran, Iran  \n4Student Research Committee, Shahid Beheshti University of Medical Sciences, Tehran, Iran  \n5Department of General Surgery, Tehran University of Medical Sciences, Cancer Institute, Tehran, Iran  \n6Department of Anesthesiology and Intensive Care, Tehran University of Medical Sciences, Tehran, Iran  \n7Skin Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran  \nCorresponding Author:  \nMohammad Abdolahad, PhD, Nano Electronic Center of Excellence, Nano Bio Electronic Devices Lab, School of Electrical and Computer Engineering, College of Engineering, University of Tehran, P.O. Box: 14395/515, Tehran, Iran; UT and TUMS Cancer Electronics Research Center, Tehran University of Medical Sciences, Tehran, Iran.  \nEmai[ls: m.abdolahad@ut.ac.ir](ls: m.abdolahad@ut.ac.ir); [abdolahad@sina.tums.ac.ir](abdolahad@sina.tums.ac.ir)  \nCreative Commons CC BY: This article is distributed under the terms of the Creative Commons Attribution 4.0 License ([https://](https://)[ ](https://)[creativecommons.org/l](creativecommons.org/l)icenses/by/","cbCaikfZAnn6OmVL","https://ap.wps.com/l/cbCaikfZAnn6OmVL","pdf",2250027,12,"English","# Abstract\n## Purpose\n## Methods\n## Results\n## Conclusion\n# Introduction\n## Epidemiology and treatment challenges\n## Mechanism of electroporation\n## Rationale for electrochemotherapy","[{\"question\":\"What skin cancer types were evaluated in this electrochemotherapy study?\",\"answer\":\"The study evaluated basal cell carcinoma (BCC), cutaneous squamous cell carcinoma (cSCC), and melanoma.\"},{\"question\":\"How many patients and nodules were assessed, and what were the response outcomes after the first month?\",\"answer\":\"Twenty-six patients were included and 104 nodules were assessed. Clinical complete response occurred in 53 lesions and partial response in 51 lesions after the first month.\"},{\"question\":\"What adverse effect was most common, and how was it characterized in the results?\",\"answer\":\"Pain was the most common adverse effect, occurring in 65% of cases, and side effects were predominantly temporary.\"}]","Electrochemotherapy for Recurrence and/or Metastatic Skin Cancers - A Prospective Case Series in Iran | PDF",1790161011]